TEST:

COLVERA™

Hypermethylated DNA biomarkers BCAT1, IKZF1 and SEPT9 were largely stable across different stages of disease and were highly selective for gastrointestinal adenocarcinomas relative to other cancer types. Existing CRC methylated ctDNA blood tests for BCAT1/IKZF1 and SEPT9 might be usefully repurposed for use in other gastrointestinal adenocarcinomas and warrant further prospective ctDNA studies.

P=NA | N=48 | "Clinical Genomics...announced a new publication from researchers at the prestigious Flinders Centre for Innovation in Cancer, Flinders Medical Center in Adelaide, S. Australia on COLVERA...This observational study provides further data to support the use of COLVERA to monitor patients throughout their CRC journey; Quantification of methylation levels of COLVERA correlates to tumor burden at diagnosis"

This change in the COLVERA interpretation rule resulted in optimized clinical specificity with minimal impact on sensitivity . For an assay intended to aid in surveillance and early recurrence detection, improved accuracy allows the physician to have increased confidence in making actionable decisions based on test result, including further imaging or treatment.

This prospective study showed that COLVERA ( a two-gene ctDNA assay) was more sensitive for detection of recurrence in a cohort of patients undergoing surveillance after definitive therapy for stages II and III CRC.

Subsequently the rare diagnosis of a sarcoidosis-like reaction from oxaliplatin-based chemotherapy was made. Repeat imaging after 3 months showed resolution of the hepatosplenic lesions and lymphadenopathy, alike.

In a population familiar with FIT-screening, provision of a blood test either as a rescue of FIT non-participants or as an up-front choice did not increase overall participation. This might reflect a lack of awareness of the blood test for screening compared to FIT.